English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We tested for antimicrobial susceptibility of 1,317 clinical isolates of Haemophilus influenzae at a pediatric facility during 2004-2008. The percentage distribution of beta-lactamase-non-producing ampicillin (ABPC)-sensitive strain (BLNAS) was 47.8%, that of beta-lactamase-non-producing ABPC-resistant strain (BLNAR) 32.7% that of intermediately resistant strain (BLNAI) 8.9% that of beta-lactamase producing ABPC resistant strain (BLPAR) 6.8% and that of clavulanic acid/amoxicillin resistant strain (BLPACR) 3.7%. BLNAR prevalence was 30% between 2005 and 2008, increasing slowly. Though reduced susceptibility was seen in most beta-lactams, piperacillin and tazobactam/piperacillin showed good susceptibility for H. influenzae. Of 1,317 strains, 83 (6.3%) were serotype b (Hib). The frequency of Hib was high in sterilized site.

Susceptibility Testing for <i>Haemophilus influenzae </i>Isolated from Pediatric Cases during 2004-2008